A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials

The study's objectives were to assess the predictive significance of different sets of demographic, clinical and extraclinical variables in identifying multiple sclerosis patients with various risk levels of worsening during the follow-up, in order to provide clues to inclusion criteria and selection of primary clinical end-points in therapeutic trials. Two hundred and twenty-four patients at their first diagnosis of multiple sclerosis admitted to our Department between 1983 and 1990 were prospectively followed-up until the end of 1996. We considered as end-points time to reach non-reversible disability levels corresponding to EDSS scores of 4.0 and 6.0 and the beginning of a secondary progressive phase in the relapsing-remitting subgroup of patients. For the statistical treatment of our data we used the Kaplan-Meier survival curves and the Cox regression analysis. An initially progressive course and higher basal EDSS scores proved to be the best predictors of unfavorable prognosis; a greater number of functional systems involved at onset as well as higher residual deficits in pyramidal, visual, sphincteric and cerebellar systems were other factors predictive of a poor outcome, whereas sensory system involvement turned out to be favorable. In the relapsing-remitting subgroup, a longer first inter-attack interval was associated with a better prognosis; however, overall number of relapses in the first two years of the disease was of no prognostic value. The presence of oligoclonal banding in the cerebrospinal fluid and a cerebral MRI 'strongly suggestive' or 'suggestive' of MS in the early phases of the disease were associated with a higher probability of a worse outcome.

[1]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[2]  M. Carreras,et al.  A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[3]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.

[4]  E. Thompson,et al.  The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis , 1991, Annals of neurology.

[5]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. , 1989, Brain : a journal of neurology.

[6]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[7]  D. Bourdette,et al.  Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) , 1992, Neurology.

[8]  A V Swan,et al.  An assessment of disability rating scales used in multiple sclerosis. , 1991, Archives of neurology.

[9]  J. Hillert,et al.  Optic neuritis , 1998, Neurology.

[10]  Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis , 1992 .

[11]  S. Cole,et al.  The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis , 1998, Neurology.

[12]  F. Munschauer,et al.  Clinical and magnetic resonance imaging in optic neuritis , 1991, Neurology.

[13]  D. Li,et al.  Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: A prospective 2‐year follow‐up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT , 1991, Neurology.

[14]  J. Baskerville,et al.  Meta-analysis of the placebo-treated groups in clinical trials of progressive MS , 1996, Neurology.

[15]  H. McFarland,et al.  Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions , 1993, Annals of neurology.

[16]  L. Fratiglioni,et al.  Inter and intra-observer reliability in Kurtzke scoring systems in multiple sclerosis. , 1987, Italian journal of neurological sciences.

[17]  B. Ford,et al.  Long‐term follow‐up of acute partial transverse myelopathy , 1992, Neurology.

[18]  G. Ebers McAlpine's Multiple Sclerosis , 1998 .

[19]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[20]  L. Fratiglioni,et al.  Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. , 1988, Archives of neurology.

[21]  A. A. Eisen,et al.  MRI in the diagnosis of MS , 1988, Neurology.

[22]  D. Miller,et al.  The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. , 1993, Brain : a journal of neurology.

[23]  A J Thompson,et al.  Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.

[24]  R. Kikinis,et al.  Longitudinal MRI in multiple sclerosis , 1994, Neurology.

[25]  D. Mcalpine The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. , 1961, Brain : a journal of neurology.

[26]  G. Aimard,et al.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. , 1980, Brain : a journal of neurology.

[27]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[28]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.

[29]  R. Rudick,et al.  Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. , 1989, Archives of neurology.

[30]  J. Noseworthy,et al.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial , 1990, Neurology.

[31]  O. Andersen,et al.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.